2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…2015 American Transplant Congress
Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe
Background: The effectiveness and safety of induction with basiliximab (IL2RA) in sensitized kidney transplant recipients is not clearly established. The aim of this study was…2015 American Transplant Congress
Kidney Vs. Heart Calculated PRA (CPRA) for Sensitized Heart Candidates: Does Donor Ethnic Distribution Make a Difference?
Background: CPRA, which is used for deceased donor (DD) kidney (KI) and pancreas/kidney-pancreas (PA/KP) allocation, is computed with KI DD HLA and ethnic frequencies. CPRA…2015 American Transplant Congress
Molecular Features of Kidney Transplant Biopsies Without Allograft Injury in Relation With Type of Induction Therapy
Objective: Molecular evidence of allograft injury might precede histopathological findings of allograft injury. We aimed to investigate if the type of induction therapy effect intragraft…2015 American Transplant Congress
The Differential Effect of HLA-DQ Mismatching on Renal Allograft Survival in Zero HLA-A,B,DR Mismatched Deceased Donor Transplants
1University of Florida, Gainesville; 2University of Kansas, Kansas City.
The role of HLA-DQ matching in renal graft survival is not well understood and difficult to interpret in the presence of other HLA antigen mismatches.…2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Post-Kidney Allograft Nephrectomy Anti-HLA Immunization Is Not Due to a Release of Anti-HLA Antibodies from the Failed Kidney
Background and aims: The reasons for the increased incidence of de novo anti-HLA donor specific antibodies (DSAs) that is observed after kidney allograft nephrectomy (NTx)…2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…2015 American Transplant Congress
What Can UNOS Data Tell Us About Patient Outcomes After Primary Renal Allograft Failure?
Evidence based approaches to patient care after Renal Allograft Failure do not exist, despite this being a high mortality period. Access to retransplantation is important…